ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Transcription Factor HOXC11 Drives Colorectal Cancer Progression and Metastasis via CAMK2A-Dependent CXCL5 Upregulation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer mortality, and the molecular drivers of progression and distant metastasis are incompletely understood. By integrating differential expression and survival analyses of TCGA CRC cohorts with HOX family genes, we identified HOXC11 as a key metastasis-associated factor. HOXC11 was markedly upregulated in CRC tissues and cell lines, with higher expression in metastatic lesions than in primary tumors, and elevated HOXC11 correlated with poor patient prognosis. HOXC11 functionally increased CRC cell proliferation, migration, and invasion in vitro and facilitated tumor growth and metastasis in vivo. Mechanistically, HOXC11 directly bound to the CAMK2A promoter and transactivated CAMK2A, leading to increased phosphorylated CAMK2A and initiation of the NF-κB pathway, which facilitated p65 nuclear translocation and induced CXCL5 expression to drive CRC progression. Conversely, CXCL5 signaling through CXCR2 upregulated HOXC11 via the ERK1/2-SP1 axis, forming a positive feedback loop. Notably, combined inhibition of CAMK2A (KN-93) and CXCR2 (SB265610) significantly attenuated HOXC11-mediated proliferation and metastasis. Collectively, these findings define a HOXC11-CAMK2A-NF-κB-CXCL5 circuit as a potential therapeutic target in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.